Opko Health, Inc. Announces Appointment of David Okrongly, Ph.D. as President of its Diagnostics Business Unit
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE:OPK) is pleased to announce the appointment of David Okrongly, Ph.D. as president of its diagnostics business unit.
Dr. Okrongly brings to OPKO extensive experience developing and commercializing advanced diagnostic platforms. Prior to joining OPKO, Dr. Okrongly most recently served as chief operating officer of Exosome Diagnostics, Inc. where he was responsible for establishing product, platform and regulatory strategy for the company’s proprietary technology for purifying RNA derivatives from exosomes.
Help employers find you! Check out all the jobs and post your resume.
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE:OPK) is pleased to announce the appointment of David Okrongly, Ph.D. as president of its diagnostics business unit.
Dr. Okrongly brings to OPKO extensive experience developing and commercializing advanced diagnostic platforms. Prior to joining OPKO, Dr. Okrongly most recently served as chief operating officer of Exosome Diagnostics, Inc. where he was responsible for establishing product, platform and regulatory strategy for the company’s proprietary technology for purifying RNA derivatives from exosomes.
Help employers find you! Check out all the jobs and post your resume.